Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis is a serious manifestation of ANCA vasculitis (AAV), which occurs due to damage small blood vessels and glomeruli. The most serious complication occurs due to the progression of renal damage and the development of end-stage renal disease (ESRD). The aim of our study was to determine the derived markers NLR and PLR and indicate their significance in assessing inflammatory activity and predicting an unfavorable course.
A retrospective-prospective study included 25 patients with ANCA-GN (60% female, 40% male, mean age 60.92 ± 8.65 years). ANCA vasculitis activity was confirmed by the Birmingham Vasculitis Activity Score - BVAS 3. We included 10 patients with granulomatosis with polyangiitis (GPA) and 15 with microscopic polyangiitis (MPA). We determined the clinical and laboratory data and the treatment outcome during a follow-up period (4-120 months). The derived parameters NLR (normal range 0.78 to 3.53) and PLR (normal range 90–210) were determined in all patients.
Initial clinical and laboratory results - before therapy were: BVAS 6.91± 1.76; ESR 69.73± 41.28; CRP 65.90± 58.01; Hb 101.33± 17.45, Creatinine 400.25±220.00; p-ANCA (60% of patients) 103.17± 82.25, c-ANCA (40%) 139.21± 97.70; proteinuria 24h 1.80±1.34 g/24h, NLR 6.87± 6.82; PLR 267.47± 110.04. According to the age, the group with GPA was significantly younger (p-value = 0.002), and in this group the NLR was 7.49, and in the MPA group 5.54. The correlation of NLR with ESR and CRP was significant (p < 0.05). During the follow-up period (49.16 ± 47.39 months), 6 deaths were recorded (NLR 6.20), 7 patients had ESRD, and were on hemodialysis (3 deaths), partial remission was recorded in 12 patients (6 had one relapse and 10 patients had CKD, and 2 are still on induction therapy). Unfavorable outcome in GPA was recorded in 30% of patients and their NLR was 11.84 ± 6.26, in the MPA group 46% of patients (NLR 3.65± 0.94) and this difference was statistically significant (p=0.003), PLR was in the group with GPA 277± 52.31, in the group with MPA PLR 232.03± 142.52.
In our cohort of patients with ANCA-associated glomerulonephritis, we observed that NLR and PLR are an inexpensive laboratory biomarkers of inflammation and may be useful in identifying patients at risk of a poor prognosis, especially in patients with GPA.
